IA
CSTL icon

IFP Advisors’s Castle Biosciences CSTL Stock Holding History

IFP Advisors’s Portfolio CSTL Stock Details CSTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.43K Buy
60
+8
+15% +$178 ﹤0.01% 4382
2026
Q1 		$1.28K Hold
52
– – ﹤0.01% 4121
2025
Q4 		$2.02K Hold
52
– – ﹤0.01% 3832
2025
Q3 		$1.18K Buy
52
+16
+44% +$325 ﹤0.01% 3890
2025
Q2 		$1.27K Buy
+36
New +$666 ﹤0.01% 4122
2025
Q1 		– Sell
-161
Closed -$4.29K – 4386
2024
Q4 		$4.29K Buy
+161
New +$4.9K ﹤0.01% 2845
2023
Q3 		– Sell
-11
Closed -$151 – 3351
2023
Q2 		$151 Hold
11
– – ﹤0.01% 3332
2023
Q1 		$235 Hold
11
– – ﹤0.01% 3261
2022
Q4 		$1K Buy
+11
New +$255 ﹤0.01% 4308

Other funds holding CSTL

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $123B AUM 45.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
SPPAM
Summit Partners Public Asset Management Boston, Massachusetts $5.69B AUM 259.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

IFP Advisors's CSTL Position: Q2 2026 in Review

IFP Advisors increased its Castle Biosciences (CSTL) stake by 15% in Q2 2026, buying an estimated $178 and bringing the position to 60 shares worth $1.43K. The position accounts for ﹤0.01% of the portfolio, ranked #4382.

IFP Advisors first reported a position in CSTL in Q4 2022 and has held it in 9 quarters since. The position peaked at $4.29K in Q4 2024. 177 funds tracked by Wall St. Rank hold CSTL as of Q2 2026.

  • IFP Advisors held 60 shares of Castle Biosciences worth $1.43K as of Q2 2026.
  • IFP Advisors bought 8 Castle Biosciences shares in Q2 2026, an estimated $178.
  • Castle Biosciences made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4382 holding.
  • IFP Advisors first reported a position in Castle Biosciences in Q4 2022 and has held it in 9 quarters since.
  • IFP Advisors's Castle Biosciences position peaked at $4.29K in Q4 2024.
  • 177 funds tracked by Wall St. Rank held Castle Biosciences as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.